Blood Screening Market - By Product (Reagents & Kits [NAT, ELISA], Instruments), Technology (Serology/Immunoassays, Rapid Test, Western Blot Assays, NGS), End-use (Hospitals, Blood Banks, Pathology Laboratories) – Global Forecast, 2024-2032

Blood Screening Market - By Product (Reagents & Kits [NAT, ELISA], Instruments), Technology (Serology/Immunoassays, Rapid Test, Western Blot Assays, NGS), End-use (Hospitals, Blood Banks, Pathology Laboratories) – Global Forecast, 2024-2032

Blood Screening Market Size

Blood Screening Market size was valued at around USD 3.2 billion in 2023 and is anticipated to register a CAGR of 7.3% between 2024 and 2032. This robust market growth can be attributed to various factors, including the continual technological advancements, rise in blood donation activities, increasing prevalence of infectious diseases, surging demand for blood transfusion diagnostics procedures, and growing healthcare infrastructure.
 

Moreover, the continuous incidences of infectious diseases such as HIV, hepatitis, and syphilis needs strict blood screening methodology. As these diseases can spread through blood transfusions, proper screening is critical in preventing their propagation. For instance, according to World Health Organization (WHO), by the end of 2022, around 39.0 million individuals were infected with HIV. Out of which 1.5 million are HIV-positive children (0-14 years old).
 

Furthermore, an increase in medical operations, surgeries, and treatments, such as organ transplants and cancer therapies, contributes to a greater need for safe and appropriate blood-related products. Thus, there is a greater demand for complete blood testing at regular intervals for patients undergoing different treatments.
 

Blood screening refers to the process of testing a blood sample to assess various parameters and detect the presence of specific substances or conditions within the blood. The main objectives of blood screening is to ensure the safety of blood transfusions, identify potential health issues, and monitor specific markers that may indicate diseases or infections.
 

COVID-19 Impact

The COVID-19 pandemic had a slightly positive impact on the blood screening market. Owing to the growing awareness towards infectious disease diagnostics has underscored the critical importance of rigorous blood screening protocols, contributing to increased demand for screening services to ensure the safety of blood transfusions. Additionally, the pandemic has prompted innovations in point-of-care testing and accelerated the adoption of automation in different screening processes. Overall, the market has experienced shifts in demand, technological emphasis, and operational strategies as it continues to adapt to the evolving healthcare landscape shaped by the global health crisis.
 

Blood Screening Market Trends

The continuous technological advancements, such as the integration of nucleic acid testing (NAT) and other molecular diagnostic techniques, growing demand for point-of-care testing, rising need for infectious disease screening, and surging demand for integrated artificial intelligence (AI) in healthcare and machine learning applications. These factors collectively contribute to the evolving landscape of the market.
 

• Point-of-care testing method is becoming more popular, allowing for rapid and decentralized blood screening. POCT enables quick decisions in a variety of healthcare settings, including rural or resource-limited settings, emergency rooms, and clinics, thus, reducing the time necessary to receive data.
   
• Moreover, AI and machine learning tools are currently being incorporated into blood screening systems for data analysis, pattern identification, and predictive analytics. These technologies improve the accuracy of screening results and help identify subtle trends related with various health issues.
   

Blood Screening Market Analysis

The market by product is segmented into reagents & kits, and instruments. The reagents & kits segment is further divided into NAT reagents & kits, ELISA, and other reagents & kits. The reagents & kits segment accounted for majority revenue share and was valued at around USD 2.4 billion revenue in 2023.
 

• The growing focus on blood donation activities is a key driving factor for reagents and kits demand. As more people participate in blood donation programmes, there is a greater demand for screening reagents and kits to assure the safety and compatibility of donated blood.
   
• Moreover, automation and technology integration in blood screening procedures requires the use of specialised reagents and kits that are compatible with automated systems. Automation improves screening process efficiency, reduces mistakes, and boosts throughput, thereby, improving overall efficiency.

Based on technology, the blood screening market is categorized into nucleic acid test, serology/immunoassays, rapid test, western blot assays, and next generation sequencing. The nucleic acid test segment is further bifurcated into transcription-mediated amplification and real-time PCR. The serology/immunoassays segment in further divided into chemiluminescence immunoassay, fluorescent immunoassays, and colorimeter immunoassays/ELISA. The nucleic acid test segment dominated the market and accounted for over 43% business share in 2023 and is anticipated to witness significant growth during the forecast period.
 

• Nucleic acid tests offer higher sensitivity and specificity compared to traditional screening methods. Their ability to detect very low levels of viral or bacterial genetic material makes them crucial for early and accurate detection of infections, including HIV, hepatitis, and other transfusion-transmissible diseases.
   
• Additionally, NAT significantly reduces the window period compared to other screening methods, ensuring a shorter timeframe during which infections might go undetected, thereby contributing to the segmental growth. The window period refers to the time between start of infection and when the infection becomes detectable.
   

The blood screening market by end-use is categorized into hospitals, blood banks, and pathology laboratories. The blood banks segment accounted for over USD 1.7 billion revenue size in 2023.
 

• The increasing need for blood transfusions, which is being driven by an ageing population, medical procedures, surgeries, and the treatment of numerous medical problems such as cancer and anaemia, highlights the need for stringent blood screening in blood banks.
   
• Furthermore, blood banks conduct blood typing and compatibility testing to ensure the donated blood is compatible with the blood type of the recipient. The need to avoid adverse responses during transfusions drives the demand for reliable blood type and compatibility testing.

North America blood screening market accounted for USD 1.3 billion revenue in 2023 and is predicted to witness substantial market progression.
 

• The region experiences a consistently high demand for blood and blood products due to factors such as presence of considerable target population for different disorders, medical procedures, surgeries, trauma cases, and the prevalence of chronic diseases. The need for a secure and robust blood supply system fuels the adoption of advanced blood screening practices.
   
• Furthermore, North America is at the forefront of technological innovation in healthcare. The region witnesses continuous advancements in blood screening technologies, including nucleic acid testing (NAT), automated immunoassays, and state-of-the-art laboratory equipment. The adoption of such advanced mechanisms is driven by a commitment to providing cutting-edge healthcare solutions.
   

Blood Screening Market Share

The blood screening industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products based on different technologies is among a key market strategy. Some of the leading industry players including Abbott Laboratories, F. Hoffmann-La Roche Ltd., Grifols, S.A., Hologic, Inc., QIAGEN N.V., among others have a notable presence in the market.
 

Blood Screening Market Companies

Some of the eminent market participants operating in the blood screening industry include

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd. 
• Grifols, S.A.
• Hologic, Inc.
• QIAGEN N.V.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Siemens Healthineers AG
• Thermo Fisher Scientific, Inc.
• SOFINA s.a (Biomerieux)
• Danaher Corporation
• Ortho-Clinical Diagnostics, Inc.
• DiaSorin S.p.A.
   

Blood Screening Industry News

• In March 2023, Abbott received FDA approval for the commercially accessible laboratory traumatic brain injury (TBI) blood screening, making it widely available to hospitals in the U.S. The test was conducted with Abbott's Alinity I laboratory device, that provides medical professionals with an objective means to rapidly diagnose individuals suffering from mild TBIs.
   
• In July 2023, Quest Diagnostics has announced the launch of the AD-Detect test for Alzheimer's disease. It is a consumer-purchased blood test that helps determine the possible risk of getting Alzheimer's disease based on a brain protein that contributes to the disorder.
   

Blood screening market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments

Click here to Buy Section of this Report

By Product, 2018-2032 (USD Million)

• Reagents & kits
  • NAT reagents & kits
    • Enzymes & polymerases
    • Standards & controls
    • Probes & primers
    • Buffer, Nucleotides, and solutions
    • Labelling & detection reagents
  • ELISA
    • Immunosorbents
    • Controls
    • Conjugates
    • Substrates
    • Sample diluents & wash solutions
  • Other reagents & kits 
• Instruments

By Technology, 2018-2032 (USD Million)

• Nucleic acid test
  • Transcription-mediated amplification
  • Real-time PCR 
• Serology/immunoassays
  • Chemiluminescence immunoassay
  • Fluorescent immunoassays
  • Colorimeter immunoassays/ELISA
• Rapid test
• Western blot assays
• Next generation sequencing

By End-use, 2018-2032 (USD Million)

• Hospitals
• Blood banks
• Pathology laboratories

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East & Africa